BeiGene/No­var­tis tout new PD-1 da­ta; No­var­tis plans down­siz­ing in Tokyo

BeiGene and No­var­tis are con­tin­u­ing to build out da­ta for its PD-1 in­hibitor tislelizum­ab, and on Mon­day re­vealed its newest Phase III topline re­sults.

At the in­ter­im analy­sis, tislelizum­ab plus chemother­a­py beat out chemo alone on the pri­ma­ry of over­all sur­vival in first-line pa­tients with lo­cal­ly ad­vanced, un­re­sectable or metasta­t­ic gas­tric or gas­troe­sophageal junc­tion ade­no­car­ci­no­ma. Ad­di­tion­al fol­low-up is need­ed for the in­tent-to-treat pop­u­la­tion, BeiGene not­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER